SUBSTANTIATION FOR THE OPTIMAL STRATEGY OF RISK MANAGEMENT IN MARKETING COMMUNICATIVE ACTIVITIES OF PHARMACEUTICAL ENTERPRISES BASED ON MATHEMATICAL MODEL APPROACH

© A. Olkhovska, V. Malyi, I. Storozhenko

1. Introduction
The modern marketing environment generates additional elements of uncertainty, expands the areas of risk situations. Under these conditions, there appears ambiguity and uncertainty in obtaining the expected result with further increased risk level in the activity of all market participants. Functioning of pharmaceutical enterprises under the current state of the Ukrainian economy necessitates their adapting to possible risk situations in the external and internal environment. The marketing communication activities play an important role in providing timely responses and making sound decisions about choosing risk management strategy.

2. Formulation of the problem in a general way, the relevance of the theme and its connection with important scientific and practical issues
An important component in managing pharmaceutical manufacturing enterprises marketing activities is the level of development and application of marketing communications in medicine products promotion. This is of particular importance when there is considerable uncertainty and organization’s environment volatility while introducing new products. Therefore, an urgent problem for the top management of the pharmaceutical enterprise is to take the sound managerial decisions to minimize the risks associated with the introduction and promotion of new medical products in the market using marketing communications, the need to choose the best methods for the risks evaluation ensuring the accuracy and reliability of the expected results.

3. Analysis of recent studies and publications in which a solution of the problem and which draws on the author
The issues of risk management in various fields of activity of pharmaceutical organizations were covered in scientific publications of national and foreign researchers including. In particular, the paper [1] presents a research aimed at studying and assessing the risks accompanying the emergence and promotion of new drugs to the market. The work [2] is devoted to the management of the risks associated with innovation in pharmacy and with the issues related to the quality of medicines. The author [3] presents practical experience of applying the risk management system in activities of pharmaceutical enterprises. The papers [4, 5] contains the structure of internal risk-oriented audits of the pharmaceutical quality system. In the paper [6], the author classifies the factors influencing the level of investment risks in the pharmaceutical sector. The author [7] presents risk management pharmaceutical company experience.
4. Allocation of unsolved parts of the general problem, which is dedicated to the article

However, the results of the analysis of advances and development results of national and foreign pharmacists indicate insufficient attention to a reasonable choice of risks management strategies in marketing communication activities of pharmaceutical organizations in promoting medicine products, which determined the urgency of the chosen research, its theoretical and practical significance.

5. Formulation of goals (tasks) of article

The aim of the work is to develop a mathematical model for analyzing and assessing risks in marketing communication activities of pharmaceutical manufacturing enterprises while promoting a new medicine product in the market under limiting and (or) saving investment funds for marketing communications. The obtained results allowed to make informed decisions as for choosing the optimal risks management strategy in marketing communication activities of pharmaceutical enterprises.

6. Statement of the basic material of the study (methods and objects) with the justification of the results

The object of research is the marketing communication activity of pharmaceutical enterprises; internal and external risks factors that may critically affect the promotion of new medicine products in the market, the volume of sales and significant marketing communications budget overrun; questionnaires of specialists in practical pharmacy.

Table 1 presents risk management strategies types and characteristics.

<table>
<thead>
<tr>
<th>Risk management strategies types</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk avoiding strategy</td>
<td>Provides complete risk elimination from program, project, plan. It is necessary to provide response principles that will prevent risk materialization. This is the “expensive” strategy, as it makes refuse from certain works for some risks; change the objectives of the program, project, plan or, in the most radical case, refuse from them.</td>
</tr>
<tr>
<td>Risk transfer strategy</td>
<td>Transfers the effects of risk materialization and responsibility for response to a third party, while the risk itself is not eliminated. This strategy almost always involves financial expenses for transfer and receipt of financial compensation in case of risk materialization.</td>
</tr>
<tr>
<td>Risk reduction strategy</td>
<td>This is the most common strategy and can be applied to any risk, as it means lower risk probability or influencing program, project, plan.</td>
</tr>
<tr>
<td>Risk taking strategy</td>
<td>There are two variants of this strategy - active and passive risk taking. Active one forms time and money reserve for the elimination of risk materialization effects. Passive one assumes the existence of an additional (backup) plan to eliminate the consequences of the problem in the event of risk materialization.</td>
</tr>
</tbody>
</table>

Source: Compiled by the author based on the materials [8–12]

Choosing the best strategy for risk management in marketing communication activities will allow pharmaceutical enterprises to concentrate and reasonably allocate investment funds for the program of new medicine products promotion, to develop appropriate measures to minimize risks.

As a tool for creating a mathematical model, we applied the theory of fuzzy simulation within Fuzzy TECH [13, 14]. The Fuzzy TECH program is freely available in the Internet. A fuzzy model development, which is the base for the top management of pharmaceutical enterprises to make sound managerial decisions on choosing the optimal risk management strategy in marketing communication activities while promoting new medicine products, contains certain steps (Fig. 1).
Analysis of the scientific literature and practical activities of the pharmaceutical market subjects established that when promoting new medicine products in the market there may be different types of risks, including violation of the planned term of the product promotion program implementation; significant budget overrun of investment funds allocated to marketing communications for the goods promotion; failure to meet planned profit indicators and sales volumes of the medicines; critical divergence of the medicine product consumer properties relative to the analogues. The emergence of these risks is possible under the risk factors that we have previously systematized and grouped into external and internal ones according to the results of the interviews with the experts of the pharmaceutical sector in the health care.

According to the experts interviewed, the risk factors are the change in the legal framework and regulation of medicinal products circulation and promotion while applying various elements of marketing communications; exchange rate change (volatility); new medicine products in the pharmaceutical market (cheaper ones); distribution of counterfeit medicines; the competitors activity to form the negative image and reputation of the pharmaceutical enterprise in the market; mistakes in marketing communications budgeting, including lack of funds; higher costs of marketing communications than income; lack of experience in medicine products promotion technologies using various elements of marketing communications in marketing service of a pharmaceutical enterprise, etc. The list of risk factors can be supplemented taking into account the relevant situation in the market and the capabilities and objectives of the pharmaceutical enterprise.

At the next stage of the model development, a qualitative and quantitative assessment of the chosen risk factors is carried out.

To make quantitative evaluation and analysis of the risk factors influence on the results of the program implementation of marketing communications in the new medicine product promotion one should determine the probability of each factor manifestation and the level of their negative effects (losses). Taking into account the high degree of uncertainty, the description of risk factors is carried out on qualitative scales, with interval estimation being used for their quantitative interpretation [15, 16].

Using the approaches proposed by the scholars [16], we have adapted the scales of quantitative assessment of risk factors influence on the results of marketing communication activities of pharmaceutical enterprises in promoting a new medicine product, which are presented in Table. 2.

Further modeling requires specific linguistic rules, that is, the corresponding input and output variables are to be described linguistically, characterizing risk factors using the corresponding term sets [13, 14]. The following fuzzy term sets were applied in the model:

1. Probability ($P$) – input variable which determines the probability of the relevant factor manifestation: {unlikely (1), possibly (2), probably (3), highly probably (4)};

2. Force ($F$) – input variable which determines the probability of the relevant factor manifestation: $F=\{\text{insignificant (1), moderate (2), critical (3), catastrophic (4)}\}$;

3. Power – an intermediate output variable characterizing the degree of factor influence on the final risk of medicinal product promotion; that is, determines the strength of one or more factors, taking into account

---

**Fig. 1. The algorithm for evaluating the risk of a new medicine product promotion program in marketing communication activities of pharmaceutical manufacturing enterprises**

1. Risk factors systematization
2. Qualitative and quantitative risk factors evaluation
3. Comprehensive evaluation of the overall marketing communications program risk when promoting a new medicine product
4. Choosing the best strategy for risk management in marketing communication

Source: Compiled by the author based on the materials 2018.
their probabilities: \( \text{Power} = \{ \text{low (1), lower than average (2), average (3), moderately high (4), high (5)} \} \).

According to the marketing objectives of the program for a new medicine product promotion, one should specify the product sales volume and the investment funds budget for marketing communications. It is necessary to evaluate the risks of promotion program implementation taking into account risk factors in the communicative marketing activities of the pharmaceutical enterprise and to choose the optimal risk management strategies.

The model uses four levels of intermediate output parameters and corresponding rules blocks: the first level is the X level, which determines the influence of each risk factor, taking into account its probabilities; the second level is the Y level, which determines the influence of the pair of factors; the third level is the Z level, which determines the influence of the whole group of factors; the fourth level is the level of external and internal factors influence “External_Power” and “Internal_Power”. The input source data is the Losses.

Then, using the expert evaluation method, one determines the probability of each analyzed risk factors manifestation and the effect of their impact on the final risk using a fuzzy rules matrix (Table 3).

### Table 2

<table>
<thead>
<tr>
<th>Scales of quantitative assessment of risk factors influence</th>
<th>Figures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Factor manifestation probability ((Probability))</td>
<td>Unlikely ((small))</td>
</tr>
<tr>
<td>Possible losses in sales of medicines, budget increase of marketing communications program (\text{(the force of factor influence on the final risk)}) ((\text{Force}))</td>
<td>Insignificant ((Low))</td>
</tr>
<tr>
<td>Losses to 10% (\leq 1)</td>
<td>Losses from 10% to 45%</td>
</tr>
<tr>
<td>Factor influence degree ((Power))</td>
<td>Low ((very_low))</td>
</tr>
</tbody>
</table>

\[\begin{align*}
1 & \quad 2 & \quad 3 & \quad 4 & \quad 5 \\
\end{align*}\]

*Source: Adapted by the author based on the materials [16]*

### Table 3

The fuzzy rules matrix of the factor degree influence on the medicine product promotion final risk

<table>
<thead>
<tr>
<th>Characteristic of factor influence on the final risk ((F))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insignificant F(1)</td>
</tr>
<tr>
<td>Unlikely, P(1)</td>
</tr>
<tr>
<td>Possibly, P(2)</td>
</tr>
<tr>
<td>Probably, P(3)</td>
</tr>
<tr>
<td>Highly probably, P(4)</td>
</tr>
</tbody>
</table>

Fuzzy TECH’s features allow to visualize the structure of the developed model and graphically present the interrelations of risk factors.

As an example of one of the risk factor, Fig. 2 shows the functions graphs of factor manifestation probability membership, depending on the term sets of the model.

Membership functions graphs of one of the risk factor impact on the final risk, depending on the term sets of the model are presented in Fig. 3.
Fig. 2. Simulating the probability of risk factor manifestation depending on the model term sets: 
- a – Unlikely; 
- b – Possibly; 
- c – Probably; 
- d – Highly probably

Fig. 3. Simulating the risk factor impact on the final risk depending on the term sets of the model: 
- a – Insignificant; 
- b – Moderate; 
- c – Critical; 
- d – Catastrophic
The final stage presents the three-dimensional surface of the fuzzy output model of the factor influence degree on the final risk, depending on the impact and manifestation probability. On the basis of the model, one of the possible risk management strategies is chosen in the marketing communication activity of the pharmaceutical manufacturing enterprise while promoting a new medicine product in the market. It is necessary to carefully choose the strategy for risk management. As a reasonable strategy for risk management in the process of strategic development of a pharmaceutical manufacturing enterprise is based on the adaptive approach to the risk management.

Fig. 4 gives an example of a three-dimensional surface of a model of fuzzy output of the factor influence degree on the final risk, depending on the impact and probability of one of the investigated risk factors manifestation.

According to simulated results, with a high probability ($P=0.77$) of one of the external factors manifestation under research in the market, its impact on the final risk is above the critical value ($F=3.25$), and the degree of the above factor impact on the final risk marketing communications program while promoting a new medicine product is rather high ($Power=4.7$). It can be stated that once the external factor under research in the market, the losses in sales volumes of a new medicine product can vary from 45 % to 55 % for a pharmaceutical enterprise.

The top management of the manufacturing pharmaceutical enterprise should not neglect a sufficiently high dependence of the external factor impact on the final risk and recommend to choose such a risk management strategy to mitigate their impact on the overall sales volumes of the new medicine product and to increase the budget for marketing communications. In our opinion, such a strategy of risk management is a strategy for active risk taking, i.e., while implementing a marketing communications program, when promoting a new medicine product in the pharmaceutical market, a reserve time and a budget for eliminating the effects of risk materialization should be formed in advance.

Approbation of the developed fuzzy model of risk analysis and evaluation has been carried out in the practical marketing communication activity of the leading national pharmaceutical manufacturing enterprise while promoting non-prescription medicine product. The developed model helped to simulate different situations of external and internal risk factors influence, quantitatively determined their influence effect, and the results of the obtained values calculated the percentage of possible losses in the medicine product sales volume and budget increase of the pharmaceutical enterprise marketing communications program.

Thus, for example, with the help of the developed mathematical model for a given advertising budget for promoting the medicine product under research and its planned sales volume, we have established that with the probability of $P=0.75$ of imposing the ban on advertising the medicine products, in particular on TV, the pharmaceutical manufacturing enterprise may experience 59.8 % of losses (Fig. 5).
Based on the results of the investigated pharmaceutical enterprise top management, we recommended to choose two optimal risk management strategies – a risk transfer strategy and a passive risk taking strategy that finally allowed to save investment funds for promoting the medicine product.

7. Conclusions

1. The model allows to evaluate the influence of certain risk factors in the marketing communications activity of pharmaceutical enterprises on the final risk of possible losses in sales volumes and higher investment funds for the marketing communications budget while promoting new medicines in the market.

2. The presented model is not vulnerable to the number of input variables – higher or lower number of risk factors leads to correspondingly higher or lower number of decision rules. There is no change in the model logic, which in its turn has a practical value for all subjects of the pharmaceutical market.

3. Thus, the proposed model allows the subjects of the pharmaceutical market to reasonably and timely evaluate the impact of individual risk factors on the results of the marketing communications program implementation when promoting a new medicine product in the market under limiting and (or) saving investment funds for the marketing communications, on the basis of the received results to make a managerial decision on choosing the optimal risk management strategy in marketing communication activities of enterprises: risk avoiding, risk transfer, risk reduction, risk taking.

References


Дата надходження рукопису 28.08.2018

Anzhela Olkhovska, PhD, Associate Professor, Department of Pharmaceutical Marketing and Management, National University of Pharmacy, Pushkinska str., 53, Kharkiv, Ukraine, 61002
E-mail: angelika.olkhovskaya@gmail.com

Volodymyr Malyi, Doctor of Pharmacy, Professor, Head of the Department, Department of Pharmaceutical Marketing and Management, National University of Pharmacy, Pushkinska str., 53, Kharkiv, Ukraine, 61002
E-mail: malyi.vladimir@gmail.com

Ihor Storozhenko, Doctor of Physical and Mathematical, Professor, Department of Physics, National University of Pharmacy, Pushkinska str., 53, Kharkiv, Ukraine, 61002
E-mail: prof.igor.storozhenko@gmail.com

DOI: 10.15587/2519-4852.2018.146473

TECHNOLOGY OF OBTAINING AND INVESTIGATION OF CHEMICAL COMPOSITION OF DENSE EXTRACT OF HAWTHORN FRUITS

© N. Sydora, S. Zuiikina, A. Kovaleva, L. Vyshnevskva

На фармацевтичному ринку України представлені різкі лікарські форми глоду, які використовуються при комплексному лікуванні серцево-судинних захворювань. Українська флора нараховує понад 30 видів глодів, серед яких достатньо сировинну базу мають неофіційні дикорослі та культурні види.

Мета. Розробити технологію одержання густих екстрактів плодів неофіційних видів глоду та встановити хімічний склад одержаних екстрактів.

Методи дослідження. Для визначення складу БАР густих екстрактів плодів глоду використовували спектрофотометричний метод та метод високоефективної рідної хроматографії (ВЕРХ).

Результати дослідження. Розроблена технологічна схема одержання густих екстрактів плодів глоду. Встановлено вміст амінокислот, флавоноїдів та гідроксикоричних кислот густих екстрактів плодів C. prunifolia Sarg., C. pseudokoryostilla Klok. та C. leiомonogyna Klok. Вміст флавоноїдів склав від 4.27 %±0,01 до 10.94 %±0,10; гідроксикоричних кислот - від 1,45 %±0,02 до 2,56 %±0,10. Методом ВЕРХ в усіх екстрактах ідентифіковано рутин, хлоргенову і ферулову кислоти. У густому екстракті плодів C. prunifolia Sarg. ідентифіковано апіген-7-О-рамнозид; C. pseudokoryostilla Klok. та C. leiомonogyna Klok. - апіген-7-О-глюкозид, апіген, лютеолін; C. leiомonogyna Klok. - лютеолін -7-О-диглікозид та кверцетин.

Висновки. Одержано густі екстракти плодів C. prunifolia, C. pseudokoryostilla та C. leiомonogyna. Вперше методом ВЕРХ в екстрактах встановлено вміст флавоноїдів та гідроксикоричних кислот. Проведено порівняльне дослідження амінокислотного складу одержаних екстрактів.

Ключові слова: глод, плоди, густі екстракти, хімічний склад, технологія, флавоноїди, гідроксикоричні кислоти, амінокислоти

1. Introduction

Genus Hawthorn (Crataegus L.) is one of the polymorphous genus of the Rosaceae L. family and its representatives are widespread in Ukraine and in the world's flora. Having analyzed the raw material base and the degree of study of Ukrainian flora hawthorns, we concluded that attention should be paid to informal wild and cultural species, as promising sources of biologically active substances (BAS).

2. Formulation of the problem in a general way, the relevance of the theme and its connection with important scientific and practical issues

As a result of the study of the chemical composition of unofficial hawthorns, we have established BAS (amino acids, phenolic compounds, organic acids), which have different types of pharmacological activity [1].